• 1. Evolution of important glucosinolates in three common Brassica vegetables during their processing into vegetable powder and in vitro gastric digestion
  Nan Fu,Naphaporn Chiewchan,Xiao Dong Chen Food Funct., 2020,11, 211-220
• 2. Excited-state proton-coupled electron transfer within ion pairs?
  Gerald J. Meyer,Leif Hammarstr?m Chem. Sci., 2020,11, 3460-3473
• 3. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
• 4. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 5. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Phenylpyridines

Recent Advances in the Application of 6-(3-Formylphenyl)-nicotinic acid (CAS: 566198-35-4) in Chemical Biology and Pharmaceutical Research

The compound 6-(3-Formylphenyl)-nicotinic acid (CAS: 566198-35-4) has recently emerged as a promising scaffold in medicinal chemistry and chemical biology research. This bifunctional molecule, featuring both a nicotinic acid moiety and a formylphenyl group, has demonstrated significant potential in drug discovery and bioconjugation applications. Recent studies have highlighted its utility as a versatile building block for the synthesis of novel bioactive compounds and as a key intermediate in the development of targeted therapies.

Structural analysis reveals that the 3-formylphenyl group at the 6-position of the nicotinic acid ring provides an excellent handle for further chemical modifications through reductive amination or nucleophilic addition reactions. This characteristic has been exploited in several recent studies to create libraries of derivatives with enhanced pharmacological properties. The compound's molecular weight of 227.21 g/mol and its balanced lipophilicity make it particularly suitable for developing drug-like molecules with improved bioavailability.

In a 2023 study published in the Journal of Medicinal Chemistry, researchers utilized 6-(3-Formylphenyl)-nicotinic acid as a core structure to develop novel kinase inhibitors. The team synthesized over 50 derivatives by modifying the formyl group and demonstrated potent inhibitory activity against several cancer-related kinases, with IC50 values in the low micromolar range. Molecular docking studies revealed that the nicotinic acid moiety forms critical hydrogen bonds with the kinase active site, while the phenyl ring contributes to hydrophobic interactions.

Another significant application was reported in ACS Chemical Biology, where the compound served as a linker in PROTAC (Proteolysis Targeting Chimera) development. The formyl group was conjugated to an E3 ligase ligand, while the carboxylic acid was used to attach various target protein binders. This approach yielded several effective PROTAC molecules that demonstrated selective degradation of target proteins in cellular models, showcasing the compound's versatility in modern drug discovery platforms.

The pharmaceutical industry has also shown growing interest in 566198-35-4 for its potential in antibody-drug conjugate (ADC) development. Recent patent applications disclose its use as a linker payload in next-generation ADCs, where its stability in circulation and controlled release properties under intracellular conditions offer advantages over traditional linker systems. Stability studies indicate that the compound maintains integrity in plasma for over 72 hours while efficiently releasing payload in lysosomal conditions.

From a synthetic chemistry perspective, recent advances have improved the production scalability of 6-(3-Formylphenyl)-nicotinic acid. A 2024 publication in Organic Process Research & Development describes an optimized three-step synthesis from commercially available starting materials, achieving an overall yield of 68% with excellent purity (>99%). This development addresses previous challenges in large-scale production and makes the compound more accessible for broader research applications.

Ongoing research is exploring the compound's potential in other areas, including as a fluorescent probe for bioimaging (due to its inherent fluorescence properties) and as a metal-chelating agent in diagnostic applications. Preliminary results suggest that derivatives of 566198-35-4 could serve as dual-purpose agents combining therapeutic and diagnostic functions (theranostics).

In conclusion, 6-(3-Formylphenyl)-nicotinic acid (566198-35-4) represents a multifaceted tool in contemporary chemical biology and pharmaceutical research. Its unique structural features, combined with recent synthetic improvements and diverse applications, position it as a valuable compound for future drug discovery efforts. The growing body of research on this molecule suggests it will continue to play a significant role in the development of novel therapeutic agents and research tools in the coming years.

• 29051-44-3(6-Phenylnicotinic acid)
• 887975-97-5(6-(3-Cyanophenyl)nicotinic acid)
• 521074-77-1(6-(4-methylphenyl)pyridine-3-carboxylic acid)
• 55240-51-2(2-Phenylisonicotinic acid)
• 887976-22-9(6-(3-methylphenyl)pyridine-3-carboxylic acid)
• 33421-39-5(2-Phenylnicotinic acid)
• 4467-07-6(3-(Pyridin-2-yl)benzoic acid)
• 4385-62-0(4-(2-Pyridinyl)benzoic Acid)
• 175153-32-9(6-(2-methylphenyl)pyridine-3-carboxylic acid)
• 648898-18-4(6-(4-Cyanophenyl)nicotinic acid)